4E2.F RELMADA THERAPEUT.DL-001
- Market cap
- -
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Is 4E2.F undervalued?
Graham numberThe Graham number of RELMADA THERAPEUT.DL-001 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
RELMADA THERAPEUT.DL-001 fundamental analysis
No fundamental analysis for RELMADA THERAPEUT.DL-001 yet.
RELMADA THERAPEUT.DL-001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About RELMADA THERAPEUT.DL-001
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, touret…
Full company profileFinancial statements of RELMADA THERAPEUT.DL-001 are not available yet.
RELMADA THERAPEUT.DL-001 dividends
RELMADA THERAPEUT.DL-001 has not paid dividends in the last 4 fiscal years.
Who owns RELMADA THERAPEUT.DL-001
- Insiders 3.23%
- Institutions 95.73%
- Public & others 1.04%
- Free float 82.6M
RELMADA THERAPEUT.DL-001 company profile
- Company name
- RELMADA THERAPEUT.DL-001
- Ticker
- 4E2.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 17
- Fiscal year end
- December
- Address
- 2222 Ponce de Leon Blvd., Coral Gables, FL, United States, 33134
- Phone
- 786 629 1376
- Website
- relmada.com
About RELMADA THERAPEUT.DL-001
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
RELMADA THERAPEUT.DL-001 management
8- Dr. Sergio Traversa M.B.A., Pharm.D.CEO & Director · born 1960
- Mr. Maged S. Shenouda M.B.A., R.Ph.Chief Financial Officer · born 1964
- Mr. Paul E. Kelly M.B.A.COO & Director · born 1957
- Mr. Charles S. Ence CPA, M.B.A.Chief Accounting & Compliance Officer · born 1965
- Ms. Gina DiGuglielmoVP & Head of Clinical Operations
- Dr. Bipin K. Dalmia MBA, Ph.D.Chief Business Officer
- Dr. Andrew CutlerSenior Clinical Development Advisor
- Dr. Richard M. Mangano Ph.D.Consultant · born 1950